At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
2.5% IL-1Ra +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis
In Brief
A Phase 2 clinical trial evaluating 2.5% IL-1Ra, Placebo, and 1 other intervention for Posterior Blepharitis. Completed, enrolled 75 participants.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety of Topical Interleukin-1-Receptor Antagonist in treatment of signs and symptoms of posterior blepharitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPosterior Blepharitis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedMay 2008
Primary CompletionMay 2010
Study CompletionOct 2010
TodayJul 2026
First PostedMay 21, 2008
Enrollment StartJan 1, 2008
Primary CompletionMay 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.1 years ago
Interventions
2.5% IL-1Radrug
2.5% custom made topical IL-1Ra three times a day in both eyes for three months
Placebodrug
custom eye drop to be applied three times a day in both eyes for three months
5% IL-1Radrug
5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months